Posible interacción gabapentina-fenitoína

Sánchez-Romero, Ana; Ja, Durán-Quintana; García-Delgado, R; Margarito-Rangel, C; Jl, Poveda-Andrés

doi:10.33588/rn.3410.2001491

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study that evaluated gabapentin as an antiepileptic [32], the authors found a trend toward higher phenytoin levels among patients receiving 900 mg/day gabapentin. Later, two case reports were published reporting clinical phenytoin intoxication with supratherapeutic plasma levels after the addition of gabapentin to 9 treatment [33,34]. Additionally, an interaction between gabapentin and felbamate, the former decreasing the clearance and increasing the half-life of the latter, has been described and attributed to competition for renal excretion [35].…”

Section: Pharmacokinetic Interactionsmentioning

confidence: 94%

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Calandre

Rico‐Villademoros

Slim

2016

Expert Review of Neurotherapeutics

187

128

View full text Add to dashboard Cite

The first two alphadelta ligands - gabapentin (GBP) and pregabalin (PGB) - were initially synthesized as antiepileptics; however, they were later also found to be useful for the treatment of additional conditions. Areas covered: Relevant publications describing potential underlying mechanisms, clinical pharmacokinetics/pharmacokinetics, and clinical efficacy and safety of these drugs in various disease conditions were searched in PubMed and Scopus and included in this review. Expert commentary: GBP and PGB are effective for the treatment neuropathic pain, fibromyalgia and epilepsy; in addition, they may be useful for the reduction of postoperative pain. PGB is also effective for the treatment of generalized anxiety disorder and GBP for the treatment of restless legs syndrome. GBP may be considered a treatment option for pain associated with Guillain-Barré Syndrome and phantom limb and for the management of uremic pruritus. Mirogabalin (MGB), recently developed, is being investigated for the treatment of peripheral neuropathic pain and fibromyalgia, showing promising results in patients with diabetic peripheral neuropathy. Their most frequent adverse reactions are of neuropsychiatric nature and include fatigue, dizziness, sedation, somnolence, and ataxia; peripheral edema and weight gain are also frequently described. Pharmacokinetic interactions are scarce; however, pharmacodynamic interactions have been described in association with drugs with CNS-depressant effects.

show abstract

Section: Pharmacokinetic Interactionsmentioning

confidence: 94%

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Calandre

Rico‐Villademoros

Slim

2016

Expert Review of Neurotherapeutics

187

128

View full text Add to dashboard Cite

show abstract

Drug-Induced Cerebellar Ataxia: A Systematic Review

et al. 2014

View full text Add to dashboard Cite

show abstract

Association between road traffic accidents and drugs belonging to the antiseizure medications class: A pharmacovigilance analysis in VigiBase

Chrétien

Nguyen

Dolladille

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims Due to their central mechanism of action, antiseizure medications (ASMs) could lead to adverse effects likely to impair driving skills. Their extended use to neuropsychiatric disorders makes it a class of drugs to monitor for their road traffic accidental (RTA) potential. We aimed to assess the reporting association between ASMs and RTAs using the World Health Organization pharmacovigilance database (VigiBase). Methods We performed a disproportionality analysis to compute adjusted reporting odds ratios to evaluate the strength of reporting association between ASMs and RTAs. A univariate analysis using the reporting odds‐ratio was used to assess drug–drug interactions between ASMs and RTAs. Results There were 1 341 509 reports associated with at least 1 ASM in VigiBase of whom 2.91‰ were RTAs reports. Eight ASMs were associated with higher reporting of RTAs compared to others (ranging from 1.35 [95% confidence interval 1.11–1.64] for lamotrigine to 4.36 [95% confidence interval 3.56–5.32] for cannabis). Eight significant drug–drug interactions were found between ASMs and the onset of RTA, mainly involving CYP450 induction. Conclusion A significant safety signal between RTAs and some ASMs was identified. Association of several ASMs might further increase the occurrence of RTA. ASMs prescription in patients with identified risk factors of RTA should be considered with caution. Study number: http://ClinicalTrials.gov, NCT04480996.

show abstract

Posible interacción gabapentina-fenitoína

Cited by 4 publications

References 0 publications

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Drug-Induced Cerebellar Ataxia: A Systematic Review

Association between road traffic accidents and drugs belonging to the antiseizure medications class: A pharmacovigilance analysis in VigiBase

Contact Info

Product

Resources

About

Posible interacción gabapentina-fenitoína

Cited by 4 publications

References 0 publications

Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Drug-Induced Cerebellar Ataxia: A Systematic Review

Association between road traffic accidents and drugs belonging to the antiseizure medications class: A pharmacovigilance analysis in VigiBase

Contact Info

Product

Resources

About

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use